Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study
CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference…
Shook & Stone Opens Up “An Ideal Lawyer’s Portrait: Representation Matters” 2026 Scholarship
Marketing 1on1 Announces the Addition of Local Citations to Its Backlink Service Offerings
Think Business, Think Hong Kong strengthens Italy-Hong Kong ties and opens new path for Asian collaboration
FUTR Announces Q1 2026 Financial Results